PAHCPhibro Animal Health Corporation

Healthcare

$38.77+1.4% 1Y

$38.77

$28.4052 weeks$59.33

Is the price fair?

Fair

Neither cheap nor expensive: cheap vs its sector, but priced for +34% a year vs +16% a year delivered.

1 good, 1 to watch, 1 neutral

What the price assumes~+34% a year

Priced for ~34% a year FCF growth. The price demands more than its three-year revenue growth of 16% a year, priced for acceleration.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 15.9 vs a 18.5 median over 40 quarters (−14% vs median).

Vs sector (EV/EBIT)7.7×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 69% of the market

FCF yieldbottom 2% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What PAHC's price assumes

Phibro Animal Health Corporation trades at 15.9× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.

15.9

Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · cheaper than the typical name in its group

Price / sales: 1.04
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 0.63%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: +34%
Growth the price implies · The price pays for +34% free cash flow growth a year for a decade; revenue has grown 16% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 4.08
EV / EBITtoday's price, trailing year to Jun 30, 2026: 7.70
EV / salestoday's price, trailing year to Jun 30, 2026: 0.99
Healthcare median P/E503 names: 27.9
Drug Manufacturers - Specialty & Generic median P/E44 names: 21.0
Free cash flow, trailing twelve months: $9.9M
Market capitalisation40.6 million shares, counted Aug 21, 2026: $1.57B
3-year revenue growth: +16%

What the market has paid for these earnings: 40 quarters of its own multiple × $2.44 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$36.10
Its own P/E history, median	$45.16
Its own P/E history, upper quartile	$56.34
52-week range	$28.40 – $59.33
Today	$38.77

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.